Separately, Peel Hunt reiterated a buy rating on shares of Motif Bio in a research note on Wednesday, August 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Motif Bio has a consensus rating of Buy and a consensus price target of GBX 107.20 ($1.40).
Shares of MTFB opened at GBX 29.35 ($0.38) on Wednesday. Motif Bio has a 12 month low of GBX 23.50 ($0.31) and a 12 month high of GBX 51.75 ($0.68).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Featured Article: Hedge Funds Explained
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.